The global expectant drugs market is witnessing robust growth, driven by an uptick in respiratory ailments, a growing aging population, and the launch of innovative over-the-counter (OTC) medications. According to a recent industry report, the global market was valued at US$ 16.4 billion in 2023 and is expected to grow at a CAGR of 4.7%, reaching US$ 27.1 billion by 2034.This growth is further...